Global health care company, Sanofi, announced Wednesday that the US Food and Drug Administration (FDA) approved the pediatric hexavalent combination vaccine, VAXELIS™ .

Image/qimono
Image/qimono

VAXELIS was developed as part of a joint partnership between Sanofi and MSD (Merck) for use  as a three dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday) for active immunization to prevent six infectious diseases–diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

Sanofi and MSD are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020.

Related: